Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 16/20 | 0.39 |
| ▸ | JAK1 | P23458 | 16/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4419835 | 0.93 | JAK2 (0.37) | JAK2JAK1KDM1AALDH1A1MEN1 | |
| SCHEMBL27648998 | 0.86 | JAK2 (0.37) | JAK2JAK1 | |
| SCHEMBL23276924 | 0.84 | JAK2 (0.48) | JAK2JAK1KDM1AALDH1A1MEN1 | |
| SCHEMBL23299665 | 0.83 | CTSL (0.38) | JAK2JAK1 | |
| SCHEMBL7608833 | 0.83 | CTSL (0.43) | MEN1KMT2A | |
| SCHEMBL4422573 | 0.81 | ALDH1A1 (0.39) | ALDH1A1MEN1TSHRKMT2AGAA | |
| SCHEMBL3370066 | 0.80 | CTSL (0.41) | — | |
| SCHEMBL6017523 | 0.79 | CTSL (0.36) | — | |
| SCHEMBL22765979 | 0.79 | P2RX7 (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL4418075 | 0.77 | ALDH1A1 (0.37) | ALDH1A1MEN1TSHRKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547705-B2 | Substituted 8′-pyri(MI)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one derivatives | SANOFI-AVENTIS (FR) | 2009-06-16 | — | — | US | disclosed |
| US-20080081820-A1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-04-03 | — | — | US | disclosed |
| US-7294631-B2 | Substituted 8′-pyri(MI)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one derivatives | SANOFI-AVENTIS (FR) | 2007-11-13 | — | — | US | disclosed |
| EP-1699795-B1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKLYMINE]-PYRIMIDO[1,2A]PYRIMIDIN-6-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2007-04-25 | — | — | EP | disclosed |
| EP-1557417-B1 | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives | SANOFI AVENTIS (FR) | 2007-03-07 | — | — | EP | disclosed |
| US-20070010539-A1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2007-01-11 | — | — | US | disclosed |
| EP-1557417-A1 | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2a] pyrimidin-6-one derivatives | Sanofi-Aventis (FR) | 2005-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010539-A1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES | GSK3B, GSK3A, PSEN1 | JAK2 394/4885JAK1 457/4885KDM1A 935/4885 |
| US-20080081820-A1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES | GSK3B, GSK3A, PSEN1 | JAK2 185/4885JAK1 152/4885KDM1A 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.